FDA Will Propose Drug GMP Quality Management Systems By December
This article was originally published in The Tan Sheet
Executive Summary
FDA expects to release a draft on improving the agency's drug GMP management systems by Dec. 1
You may also be interested in...
PAT Data Will Not Be Evaluated During Drug Inspections – FDA
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference
CDER Deputy Galson Will Run Drug Center For At Least Six Months
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches
PAT Selective Implementation Advised As Cost Control Measure
The cost to pharmaceutical manufacturers of operating process analytical technology often is more than the cost of implementing it, according to Pfizer Drug Product Technology Senior Manager Joep Timmermans